» Articles » PMID: 30598826

Post-MI Treatment with G-CSF and EPO-liposome with SLX Repairs Infarcted Myocardium Through EPCs Mobilization and Activation of Prosurvival Signals in Rabbits

Overview
Date 2019 Jan 2
PMID 30598826
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

We investigated whether combination therapy of G-CSF and erythropoietin (EPO)-liposome with Siaryl Lewis X (SLX) is more cardioprotective than G-CSF or EPO-liposome with SLX alone. For the purpose of generating myocardial infarction (MI), rabbits underwent 30 minutes of coronary occlusion and 14 days of reperfusion. We administered saline (control group, i.v.,), G-CSF (G group, 10 μg/kg/day × 5 days, i.c., starting at 24 hours after reperfusion), EPO-liposome with SLX (LE group, i.v., 2500 IU/kg EPO containing liposome with SLX, immediately after reperfusion), and G-CSF + EPO-liposome with SLX (LE + G group) to the rabbits. The MI size was the smallest in the LE+G group (14.7 ± 0.8%), and smaller in the G group (22.4 ± 1.5%) and LE group (18.5 ± 1.1%) than in the control group (27.8 ± 1.5%). Compared with the control group, the cardiac function and remodeling of the G, LE, and LE + G groups were improved, and LE + G group tended to show the best improvement. The number of CD31-positive microvessels was the greatest in the LE + G group, greater in the G and LE groups than in the control group. Higher expressions of phosphorylated (p)-Akt and p-ERK were observed in the ischemic area of the LE and LE + G groups. The number of CD34/CXCR4 cells was significantly higher in the G and LE + G groups. The cardiac SDF-1 was more expressed in the G and LE + G groups. In conclusion, Post-MI combination therapy with G-CSF and EPO-liposome with SLX is more cardioprotective than G-CSF or EPO-liposome with SLX alone through EPCs mobilization, neovascularization, and activation of prosurvival signals.

Citing Articles

Efficacy and safety of saponin injection in the treatment of acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials.

Chen P, Gao Z, Guo M, Pan D, Zhang H, Du J Front Pharmacol. 2024; 15:1353662.

PMID: 38576488 PMC: 10991745. DOI: 10.3389/fphar.2024.1353662.


Effects of electrically conductive nano-biomaterials on regulating cardiomyocyte behavior for cardiac repair and regeneration.

Morsink M, Severino P, Luna-Ceron E, Hussain M, Sobahi N, Shin S Acta Biomater. 2021; 139:141-156.

PMID: 34818579 PMC: 11041526. DOI: 10.1016/j.actbio.2021.11.022.


Nanoparticle delivery of cardioprotective therapies.

Mendez-Fernandez A, Cabrera-Fuentes H, Velmurugan B, Irei J, Boisvert W, Lu S Cond Med. 2021; 3(1):18-30.

PMID: 34268485 PMC: 8279025.


Mobilization of endothelial progenitor cells promotes angiogenesis after full thickness excision by AMD3100 combined with G-CSF in diabetic mice by SDF-1/CXCR4 axis.

Lin X, Wang H, Li X Diab Vasc Dis Res. 2021; 18(2):14791641211002473.

PMID: 33779350 PMC: 8481732. DOI: 10.1177/14791641211002473.


Post-MI treatment with G-CSF and EPO-liposome with SLX repairs infarcted myocardium through EPCs mobilization and activation of prosurvival signals in rabbits.

Yamada Y, Minatoguchi S, Endo N, Kanamori H, Kawasaki M, Nishigaki K Pharmacol Res Perspect. 2019; 7(1):e00451.

PMID: 30598826 PMC: 6302719. DOI: 10.1002/prp2.451.

References
1.
Ripa R, Jorgensen E, Wang Y, Thune J, Nilsson J, Sondergaard L . Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial.... Circulation. 2006; 113(16):1983-92. DOI: 10.1161/CIRCULATIONAHA.105.610469. View

2.
Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M . Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res. 2008; 79(4):611-20. DOI: 10.1093/cvr/cvn154. View

3.
Zhao Z, Corvera J, Halkos M, Kerendi F, Wang N, Guyton R . Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003; 285(2):H579-88. DOI: 10.1152/ajpheart.01064.2002. View

4.
Zohlnhofer D, Ott I, Mehilli J, Schomig K, Michalk F, Ibrahim T . Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA. 2006; 295(9):1003-10. DOI: 10.1001/jama.295.9.1003. View

5.
Suzuki K, Nagashima K, Arai M, Uno Y, Misao Y, Takemura G . Effect of granulocyte colony-stimulating factor treatment at a low dose but for a long duration in patients with coronary heart disease. Circ J. 2006; 70(4):430-7. DOI: 10.1253/circj.70.430. View